Thiagaraj Ashwin K, Malviya Meenal, Htun Wah W, Telila Tesfaye, Lerner Stephen A, Elder Mahir D, Schreiber Theodore L
Department of Cardiology, Harper University Hospital, 3990 John R Rd, 4 Hudson, Detroit Medical Center, Wayne State University, Detroit, MI 48201, USA.
Department of Infectious Diseases, Harper University Hospital, 3990 John R Rd, 5 Hudson, Detroit Medical Center, Wayne State University, Detroit, MI 48201, USA.
Future Cardiol. 2017 May;13(3):211-217. doi: 10.2217/fca-2016-0076. Epub 2017 Mar 22.
The AngioVac is a vacuum-based device introduced in 2012 to percutaneously remove undesirable material from the intravascular system. In scattered reports, the AngioVac has been used for removal of device-led vegetations and right-sided thrombi. In this article, we describe three cases of right-sided endocarditis treated with AngioVac: a mobile mass extending from the vena cava into the right atrium, large native tricuspid vegetations, and bioprosthetic tricuspid vegetations. This device shows benefit in reducing vegetation load, decreasing septic lung embolization, and reducing reinfection in active intravenous drug users. These cases exhibit the AngioVac's arrival as a new and exciting tool in endocarditis treatment, providing an alternative to open surgery and accessorizing antimicrobial treatment.
AngioVac是一种于2012年推出的基于真空的设备，用于经皮从血管系统中清除不良物质。在一些零散的报告中，AngioVac已被用于清除器械相关赘生物和右侧血栓。在本文中，我们描述了3例使用AngioVac治疗的右侧心内膜炎病例：一个从腔静脉延伸至右心房的活动团块、大型原发性三尖瓣赘生物以及生物瓣三尖瓣赘生物。该设备在降低赘生物负荷、减少脓毒性肺栓塞以及降低活跃静脉吸毒者的再感染方面显示出益处。这些病例展示了AngioVac作为心内膜炎治疗中一种全新且令人振奋的工具的出现，为开放手术提供了一种替代方案，并辅助抗菌治疗。
